|
||
|
Incara Pharmaceuticals
Download PDF Members: Incara Pharmaceuticals Corporation focuses on the protection and regeneration of tissue damaged by injury and disease. The company currently has programs in three areas: liver cell therapy and progenitor cell therapy as a treatment for liver failure; small molecule catalytic antioxidants as treatment for stroke and tissue damage; and deligioparin (formerly named OP2000), an ultra-low molecular weight heparin being developed with Elan Corporation for treatment of ulcerative colitis.
This page has been viewed 408 times since April 2007, the link to the organisation's website has been followed 83 times Recent Search Terms used to find this page: incara pharma | Incara Pharmaceuticals | Incara Pharmaceuticals | incara | Incara Pharmaceuticals | incara | Incara Pharmaceuticals | incara | Incara Pharmaceuticals | Incara Pharmaceuticals 27709 | . This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Incara Pharmaceuticals | |||||||||||||||||||||||||||||||||||||||||
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement |
All rights reserved. All other trademarks recognized. |
|
|